Home / Health / Zolgensma Linked to Tumors in Children
Zolgensma Linked to Tumors in Children
6 Nov
Summary
- Two children developed tumors linked to Zolgensma treatment.
- Nine tumor reports surfaced since the drug's 2019 approval.
- Zolgensma treats the deadly condition spinal muscular atrophy.
Children receiving Novartis's Zolgensma gene therapy for spinal muscular atrophy have developed tumors, with two cases definitively linked to the treatment.
Since the drug's approval in 2019, a total of nine tumor reports have been filed involving patients who had undergone Zolgensma treatment.
This therapy is intended for the treatment of the deadly condition known as spinal muscular atrophy, and these developments are prompting scrutiny.
Disclaimer: This story has been auto-aggregated and auto-summarised by a computer program. This story has not been edited or created by the Feedzop team.
